Hemostemix: Up-Listing in the USA to Generate Liquidity and Expand Reach

Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VF0) has announced its application to up-list to the OTCQB Venture Market, aiming to increase liquidity across USA, European, and Canadian markets. This strategic move is expected to enhance the company's visibility and accessibility to a larger investor base, ultimately driving growth and value for the company.

Hemostemix's innovative stem cell therapeutics platform, including ACP-01, NCP, and CCP, has shown promising results in clinical trials. The company's ACP-01 therapy has demonstrated significant efficacy in treating peripheral arterial disease (PAD) and critical limb ischemia (CLI). In a Phase II clinical trial, 83% of patients experienced healing of ulcers, cessation of pain, no major amputation, and improved cardiac function. The global market for Hemostemix's therapies is substantial, with 236 million people suffering from PAD and 23 million developing CLI, highlighting the potential for the company to tap into this vast market and provide life-saving treatments to patients in need.

The up-listing on the OTCQB Venture Market will provide Hemostemix with better access to U.S. capital markets, which can be beneficial for raising funds and expanding the company's operations. By increasing liquidity, broadening the investor base, and improving visibility, Hemostemix may be able to achieve a higher valuation for its shares, helping the company raise more capital and fund its growth initiatives.

Hemostemix's social media campaign across Instagram, Facebook, LinkedIn, YouTube, and X highlights the successful patient treatments for limb salvation, heart function regeneration, and vascular dementia using its ACP-01 therapy. Individual patients share their experiences, connecting with millions of potential patients who may benefit from ACP-01 treatments under special access programs. This testimonial-driven approach emphasizes the real-world impact of Hemostemix's therapies and positions the company as an attractive investment opportunity.

Hemostemix's strategic partnership with CytoImmune Therapeutics will re-establish production of ACP-01 in CytoImmune's state-of-the-art clinical cell manufacturing facility. This partnership underscores CytoImmune's dedication to fostering partnerships that fuel the future of cell therapy and improve patients' lives. Hemostemix expects this partnership to enable the company to ramp up production with CytoImmune and its own staff, reaching sales volumes of up to $2 million per month in 2025.

In conclusion, Hemostemix's up-listing on the OTCQB Venture Market is a strategic move to generate liquidity and expand its reach across the USA, European, and Canadian markets. By increasing visibility, accessibility, and potential valuation, Hemostemix aims to tap into the vast market for its innovative stem cell therapeutics platform, ultimately driving growth and value for the company. The company's successful patient testimonials, strategic partnerships, and promising clinical results position Hemostemix as an attractive investment opportunity in the growing stem cell therapeutics market.